Cenegermin Eye Drops for Persistent Corneal Ulcers
Part of Eyes & vision, Immune system & allergy clinical trials.
This study tests whether cenegermin eye drops help heal stubborn corneal ulcers (open sores on the clear front of the eye) that haven't improved with standard treatments like lubricating drops or contact lenses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older (19+ in South Korea)
- You have a corneal ulcer at least 1 mm across that has lasted 2+ weeks and didn't get better with standard treatments
- Your other eye can see (not completely blind)
- You don't have active eye infection, severe inflammation, or severe eyelid problems affecting the ulcer
- You haven't used cenegermin before and can avoid certain eye drops, steroids, contact lenses, and recent eye surgery during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special substance from stem cells (called secretome) can help heal chronic surface problems on the eye that haven't gotten better with standard treatments. It's for people with a stubborn scratch or defect on the cornea that has lasted more than 14 days.
This Phase 2 trial tests whether a treatment gel called NEXAGON (lufepirsen) can improve healing and safety in people with a persistent corneal problem called PCED that hasn’t gotten better despite standard non-surgical treatments. You may be a candidate if your defect has lasted at least 2 weeks and hasn’t improved recently, and if you don’t have certain eye infections or other eye conditions.
This trial compares two treatments for persistent corneal surface wounds that haven't healed with standard care. You'll receive either insulin eye drops or a special tissue graft to help your cornea heal.
This Phase 3 trial tests whether a 0.1% RGN-259 eye drop can safely improve a stubborn corneal wound in adults with neurotrophic keratopathy (nerve-related corneal healing problems). You may qualify if you still have an eye surface defect after at least a week of standard treatments, and you meet specific measurements for corneal sensitivity and vision.
This trial tests a new eye drop to see if it can safely and effectively reduce corneal scars. It is for people who have a recent corneal injury (within the last month) that resulted in a scar that affects their vision.
This Phase 2 trial tests a locally delivered cell-based treatment (allogeneic mesenchymal stromal cells) to help heal long-lasting damage to the eye’s clear surface (the cornea). It may help if your cornea epithelium (surface layer) won’t improve even after standard non-surgical treatments.
Hear when a new Persistent Corneal Epithelial Defect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.